Oncotelic Therapeutics, Inc. (OTLC)
- Previous Close
0.0587 - Open
0.0587 - Bid 0.0532 x --
- Ask 0.0580 x --
- Day's Range
0.0587 - 0.0587 - 52 Week Range
0.0200 - 0.0700 - Volume
2,500 - Avg. Volume
114,977 - Market Cap (intraday)
24.498M - Beta (5Y Monthly) -0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date May 12, 2025 - May 16, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes. The company also develops OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus. In addition, it is developing CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of support technologies. The company is headquartered in Agoura Hills, California.
www.oncotelic.comRecent News: OTLC
View MorePerformance Overview: OTLC
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: OTLC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: OTLC
View MoreValuation Measures
Market Cap
23.97M
Enterprise Value
36.97M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.90
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-0.83%
Return on Equity (ttm)
-50.08%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-4.52M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
86.13k
Total Debt/Equity (mrq)
175.03%
Levered Free Cash Flow (ttm)
-313.49k